RecruitingAge-related condition
Wake Forest Alzheimer's Disease Clinical Core (ADCC)
- Sponsor
- Wake Forest University Health Sciences (Academic or other)
- Enrollment
- 850 planned
- Conditions
- Alzheimer's Disease; Mild Cognitive Impairment; Prediabetic State
- Ages
- adults, older adults
- Registry
- NCT03140865
Full record on ClinicalTrials.gov
From the registry
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. According to this model, the best hope for countermanding the effects of AD lies in intervening at the earliest possible point in the pathological cascade. There are several important ongoing efforts in adults with preclinical AD that directly target amyloid aggregation. Although this strategy addresses an important aspect of the AD pathological cascade, we believe that addressing metabolic dysfunction affecting glucose and insulin regulation offers a complementary approach, in that it may reduce amyloid burden and toxicity, while also directly enhancing synaptic health, brain metabolism, tau…
Primary outcomes
- Change in performance on cognitive measures.
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started